Combination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer - a phase I study.

摘要: Current approaches for the improvement of bNED prostate cancer patients treated with radiotherapy mainly focus on dose escalation. However molecularly targeted may also turn out to be value. In this regard cyclooxygenase (COX)-2 inhibitors have been shown exert some anti-tumour activities in human vivo and vitro. Although vitro data indicated that combination COX-2 inhibition radiation was not associated an increased toxicity, we performed a phase I trial using high celecoxib together percutaneous therapy. order rule any increases more than 20% incidence given side effect level 22 were included trial. Celecoxib 400 mg twice daily onset treatment. Risk adapted doses between 70 74 Gy standard fractionation. RTOG based gastrointestinal (GI) genitourinary (GU) acute toxicity scoring weekly during therapy, at six weeks after therapy three month completing Generally no major increase effects potentially caused by combined treatment observed. two cases generalised skin rash occurred which immediately resolved upon discontinuation drug. No grade 3 4 seen. Maximal GI 1 2 observed 85% 10%, respectively. terms GU 80 % experienced 10 had symptoms. The irradiation concurrent effects.